X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to focus on the clinical development of IDE161, a small molecule inhibitor targeting PARG, in combination with Keyutra for the treatment of Endometrial Cancer.
Lead Product(s): IDE161,Pembrolizumab
Therapeutic Area: Oncology Product Name: IDE161
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 12, 2024
Details:
The net proceeds will fund ongoing clinical development of IDE196 (darovasertib), a protein kinase C (PKC) inhibitor, and crizotinib, as combination therapy in metastatic uveal melanoma, including our Phase 2/3 potential registrational clinical trial.
Lead Product(s): Darovasertib
Therapeutic Area: Oncology Product Name: IDE196
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $143.8 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 27, 2023
Details:
The net proceeds will fund ongoing clinical development of IDE196 (darovasertib), a protein kinase C (PKC) inhibitor, and crizotinib, as combination therapy in metastatic uveal melanoma, including our Phase 2/3 potential registrational clinical trial.
Lead Product(s): Darovasertib,Crizotinib
Therapeutic Area: Oncology Product Name: IDE196
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 24, 2023
Details:
IDE196 (darovasertib) is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. Currently being developed in combination with Crizotinib for metastatic cutaneous melanoma.
Lead Product(s): Darovasertib,Crizotinib
Therapeutic Area: Oncology Product Name: IDE196
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
Under the collaboration, IDEAYA selected werner helicase inhibitor development candidate, a potent, selective, small molecule inhibitor of the helicase domain of Werner protein and GSK will lead clinical development.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $960.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration October 09, 2023
Details:
IDE161 is a potent, selective, small-molecule inhibitor of PARG, which is investigated for the treatment of adult patients having advanced or metastatic hormone receptor positive (HR+), Her2- breast cancer.
Lead Product(s): IDE161
Therapeutic Area: Oncology Product Name: IDE161
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
IDE161 is a potent, selective, small-molecule inhibitor of PARG, a novel and mechanistically-differentiated target in the same clinically validated pathway as PARP, which is investigated in advanced or metastatic ovarian cancer with germline or somatic BRCA 1/2 mutations.
Lead Product(s): IDE161
Therapeutic Area: Oncology Product Name: IDE161
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
IDE161 is a potent, selective, small-molecule inhibitor of PARG, a novel and mechanistically-differentiated target in the same clinically validated pathway as PARP, which is investigated in HRD solid tumors.
Lead Product(s): IDE161
Therapeutic Area: Oncology Product Name: IDE161
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
GSK101 (IDE705), a small molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small molecule inhibitor of PARP for the treatment of patients having tumors with BRCA or other homologous recombination mutations.
Lead Product(s): IDE705,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: GSK101
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Details:
IDE196 (darovasertib) is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. Currently being developed for metastatic uveal melanoma.
Lead Product(s): Darovasertib
Therapeutic Area: Oncology Product Name: IDE196
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
